Global CD Antigen Cancer Therapy Market Size, Share & Trends Analysis Report By Product Type, By Type, By Therapy Type, By End-user, By Region, And Segment Forecasts, 2024 – 2031
Market Overview
Global CD Antigen Cancer Therapy Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031
CD markers, or CD antigens, are molecules found on cell surfaces that differentiate cell types. They detect abnormal growth of cells called neoplasm, which can be benign, malignant, or precancerous. CD markers are crucial in cancer diagnosis and can help identify successful treatment types and measure treatment effectiveness by monitoring changes in relevant CD markers.
Market Scope
|
Metrics |
Details |
|
CAGR |
YY% |
|
Market Size Available for Years |
2022-2031 |
|
Estimation Forecast Period |
2024-2031 |
|
Revenue Units |
Value (US$ Mn) |
|
Segments Covered |
Product Type, Type, Therapy Type, End User |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
|
Largest Region |
North America |
|
Fastest Growing Region |
Asia-Pacific |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Rise in shift towards personalized medicine
The CD Antigen Cancer Therapy market is experiencing a significant shift towards personalized medicine, with healthcare professionals choosing the most appropriate treatment based on a patient's unique biological characteristics. This approach, such as CAR-T cell therapy, directly targets the molecular characteristics of the cancer, maximizing therapy success while minimizing side effects.
The market is also expanding by exploring novel CD antigens beyond CD19 and CD20, allowing researchers to design therapies for tumors that may not respond adequately to CDI 9-targeted treatments. Advancements in gene editing technologies like CRISPR are also facilitating next-generation CAR-T therapies, allowing for precise adjustments to immune cells' genetic makeup, boosting CAR-T cell performance and endurance. These developments open the door to next-generation CAR-T therapies that improve potency, safety, and longevity, advancing our quest for more efficient cancer treatments.
Complications associated with drugs
CD Antigens drugs in cancer therapy have side effects like weakness, burning eyes, slow heart rate, chest pain, wheezing, dry cough, shortness of breath, high blood sugar, ketoacidosis, low blood cell counts, liver problems, and stomach problems. Short-acting and long-acting versions have been found to be dangerous, limiting market growth.
Segment Analysis
The global CD antigen cancer therapy market is segmented based on product type, type, therapy, end-user and region.
The monoclonal antibodies from the product type segment accounted for approximately 62.3% of the CD antigen cancer therapy market share
The monoclonal antibodies from the product type segment accounted for approximately 42.3%. Monoclonal antibodies segment is expecte to have highest market share due to their high specificity to cancer cells and ability to bind to surface proteins, are poised to gain a significant market share in the CD Antigen Cancer Therapy market due to their potential in cancer treatment.
The robust investments by global pharmaceutical entities in the research and development of cancer biologics, particularly monoclonal antibodies, reflect their efficacy and low toxicity profile compared to conventional chemotherapy. Approval procedures for new cancer monoclonal antibodies contribute to the market's expansion. For instance, the conditional approval of trastuzumab deruxtecan in the European Union for HER2-positive breast cancer treatment in January 2023 exemplifies regulatory responsiveness to innovative therapies.
Geographical Analysis
North America is estimated to hold about 42.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like robust healthcare infrastructure, coupled with high adoption rates of advanced medical technologies, and substantial investments in cancer, R&D and the adoption of cancer therapy and the significant burden of cancer cases, particularly in the United States and Canada.
For instance, data released by the Canadian Cancer Society in November 2023 revealed that approximately 239, 100 individuals in Canada were diagnosed with cancer in 2023 alone. Also, it is projected that an estimated 2 out of 5 Canadians will develop cancer at some point during their lifetime. This high prevalence highlights the urgent need for efficient remedy processes to the lead in tackling the problems caused by cancer.
Covid 19 Impact Analysis
The COVID-19 pandemic has significantly impacted the CD antigen cancer therapy market in various ways. The pandemic led to disruptions in clinical trials, with many studies being delayed or temporarily halted due to lockdowns and reallocation of healthcare resources to manage COVID-19 cases. This affected the development timelines for new therapies targeting CD antigens. Additionally, supply chain interruptions hindered the production and distribution of essential research materials and therapeutic products.
Market Segmentation
By Product Type
- Monoclonal Antibodies
- Antibody-drug conjugates
- CAR-T Cell Therapies
- Тrі-Funсtіоnаl аnd Ві-Ѕресіfіс Т-Сеll Еngаgеr Аntіbоdіеѕ
- Others
By Type
- CD19
- CD20
- CD22
- CD30
- Others
By Therapy Type
- Targeted Therapy
- Immunotherapy
- Combination Therapy
- Monotherapy
- Others
By End-User
- Hospitals
- Cancer research centers
- Clinics
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the market include Seattle Genetics Inc, АrуоGеn Віорhаrmа, Віосаd, Віоgеn Іdес, Сеlltrіоn, Gеnеntесh, Gеnmаb, Merck, Sandoz, Eli Lilly the Company among others.
Key Developments
- In April 2023, The USFDA approved Genentech, a Roche Group company, for use of Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) as a cancer therapy medication. The medication is used to treat adult patients with diffuse large B-cell lymphoma (DLBCL) who have not had prior treatment.
- In April 2023, Omisirge (omidubicel-onlv), an allogeneic cell treatment developed by Gamida Cell Ltd, was approved by the USFDA for use in treating hematologic malignancies in adults and children patients aged 12 years and above.
Why Purchase the Report?
- To visualize the global CD antigen cancer therapy market segmentation based on product type, type, therapy type, end user and region as well as understand key commercial assets and players.
- identify commercial opportunities by analyzing trends and co-development.
- excel data sheet with numerous data points of the CD antigen cancer therapy market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global CD antigen cancer therapy market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
